Research Analysts Offer Predictions for VKTX FY2029 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Leerink Partnrs reduced their FY2029 earnings estimates for Viking Therapeutics in a research report issued to clients and investors on Wednesday, April 23rd. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will earn $5.20 per share for the year, down from their previous forecast of $5.24. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share.

Several other brokerages also recently commented on VKTX. Morgan Stanley reduced their target price on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price for the company. Citigroup started coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target on the stock. Raymond James increased their target price on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Finally, Maxim Group lowered their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $25.66 on Friday. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.86. The company's 50 day simple moving average is $26.56 and its 200 day simple moving average is $40.93. The company has a market capitalization of $2.88 billion, a P/E ratio of -25.66 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). During the same period in the previous year, the business posted ($0.26) earnings per share.

Insider Transactions at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business's stock in a transaction dated Monday, March 31st. The stock was acquired at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Viking Therapeutics

Hedge funds have recently made changes to their positions in the business. S.A. Mason LLC boosted its holdings in Viking Therapeutics by 20.0% during the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock valued at $72,000 after purchasing an additional 300 shares in the last quarter. Blue Trust Inc. grew its position in Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 309 shares during the period. Bank Julius Baer & Co. Ltd Zurich raised its stake in Viking Therapeutics by 7.4% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after acquiring an additional 345 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Viking Therapeutics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock valued at $1,164,000 after acquiring an additional 353 shares during the period. Finally, HighMark Wealth Management LLC grew its holdings in shares of Viking Therapeutics by 9.4% in the 1st quarter. HighMark Wealth Management LLC now owns 4,660 shares of the biotechnology company's stock worth $113,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company's stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.